

# Investor Day 2025



## RD Saúde Day 2025 Agenda



#### Welcome

Flavio Correia Statutory Executive Director IR 05

#### **Customer Service**

Melissa Cabral Pharmacy Operations VP

**Expansion & Logistics** 

Marcello De Zagottis

Paulo Sanchez

01

#### Opening

Marcilio Pousada Chairman

06

#### **Omnichannel**

Diego Kilian Omnichannel Director 09

08

#### Technology

Fernando Varela Digital Transformation VP

02

#### First Year

Renato Raduan



#### Q&A Session 1

Start: 15:45 | End: 16:00

10

#### Market & Outlook

Renato Raduan CEO

Flavio Correia Statutory Exec. Director IR

03

#### Overview

Marcello De Zagottis COO



#### Break

Start: 16:00 | End: 16:15



#### Q&A Session 2

Start: 17:20 | End: 17:50

04

#### Customers

Daniel Campos

Executive Director of Marketing & Customers

07

#### **HPC & Private Label**

Juliana Lopes Commercial VP



#### Closing

Flávio Correia

Statutory Executive Director IR



# MARCILIO POUSADA

PRESIDENTE DO CONSELHO ADMINISTRATIVO

CHAIRMAN OF THE BOARD




# RENATO RADUAN

**CEO** 




In 2020, we developed the 2025 strategic vision to go beyond the Pharmacy and become the gateway to health and wellness.







# The new strategy, combined with the digital transformation, increased CAPEX, accompanied by the growth of structural expenses.






# The additional investment in CAPEX and G&A was supported by the greater efficiency and operating leverage generated at our pharmacies.












# Over time, the competitive environment intensified, resulting in slower sales growth, reduced market share gains, and profitability pressure.











### We defined priorities to guide the company's evolution



A careful focus on our people



However, the context lead us to create a short-term recovery plan built upon 3 pillars.

#### **Customer value proposition**

- Increased competitiveness and promotionalization
- ◆ Greater intensity in activation / CRM
- Partnering with suppliers regarding HPC assortment and pricing in marketplaces
- Improved stock availability
- ◆ Strengthened customer service Pharmacy staff
- Reduced friction in the pharmacy experience (RT)
- Specific app journey improvements

#### **Profitability & value creation**

- Greater G&A efficiency
- Online and Offline medicine pricing
- ♦ Generic medicine sourcing
- ♦ Tax efficiency, including the Goiás DC
- **♦** Reduction in **inventory losses**
- Days of inventory optimization
- ♦ Reduction of labor lawsuits
- **♦** Efficiency in GNFR purchases
- Efficiency in Digital Product development
- ♣ Improved results in invested companies


#### **Organizational improvements**

- Adjustments for a leaner, more agile, and simpler organization
- New Digital Products development model
- ♦ New IT structure
- **♦** Evolutions in the **EVP**
- Compensation & benefits package (pharmacies and DCs)
- Advancements in customer-centricity and efficiency culture
- Evolution of the Al agenda in the organization



# In the first 9 months of 2025, these efforts recovered sales performance, reduced G&A, and accelerated market share.







Source: IQVIA. Southeast excludes SP.



The focus and efforts of the team are now directed at strengthening our value proposition and our moats.

## Recovery of Performance & Efficiency

- Price and competitiveness
- HPC performance
- Enphasis on Logistics and supply
- Inventory levels and losses
- Corporate review (G&A)
- Optimization of investments in strategic initiatives
- Culture and engagement (EVP)

## Strengthening of the Value Proposition and Moats


- Evolve in our value proposition for customers
- Evolve even further in the in-store digital experiences
- Evolve in the culture of efficiency
- Evolve in the use of AI
- Advance our private labels
- Accelerate value of our adjacencies (Impulso and compounded drugs)
- Increase proximity / Expansion



We are proud of the results achieved, while recognizing that the customer, at the center of our business, sees us from a different angle.



We brought to the forefront how customers perceive us and the specific needs of each group.





## MARCELLO DE ZAGOTTIS

COO



## A new organizational structure for superior efficiency.

## RDsaúde Operations

#### **Customers**



Service



**Digital** 



**Commercial** 

**Supply** 



**51 MM** active customers

11 MM omni customers

+13.5% loyal customers

70k

employees +27k in 5 years

429 MM

LTM interactions +73% in 5 years

NPS **91**MSSS **+7.8%**Share **16.8%** 

Digital penetration **26.7%** the highest in Brazil

....

**81%** app participation

40%+ digital share

**20+ MM** orders per quarter

Recovery of **COMPETITIVENESS** in HPC

Overshare
In GLP-1

Inventory reduction

-8 days

vs. 3Q24

**-21%** 

stockout reduction

+2 DCs

contracted for 2026




# DANIEL CAMPOS

**DIRETOR EXECUTIVO DE MARKETING E CLIENTES** 

**EXECUTIVE DIRECTOR - MARKETING** 



We listen to and understand our customers, advancing our ambition to deliver the best experience.






Active customer listening



Data insights and profiling framework



We created a robust agenda of qualitative and quantitative studies, bringing the customer's voice to the center of discussions.





We are constantly evolving in how we understand and interpret different customer profiles.




51 MM active customers

A growing and qualified customer base, with unique segmentation opportunities



**Profiles** 


Characterize our main customer groups





## For each persona, an exclusive and personalized journey, with an experience and value proposition aligned to their needs.

#### **Example: Persona D**



Customer X-ray based on **quantitative data**.



Active customer listening to identify pain points and opportunities.



Designing an integrated omni journey: the best offer, the best channel, with benefits and loyalty.

We deepened our understanding of personas, activating profiles and engagement bonds, maximizing LTV across segments.

Quarterly Vision (oct/25)		Gross Rev.	Customers (YoY)	Avg. Spending (Total = index 100)
Strategic Profiles	Profile A	+20.4%	+9.6%	182
	Profile B	+16.0%	+8.0%	295
	Profile C	+20.5%	+9.4%	261
	Profile D	+20.6%	+14.9%	316
	Bond A	+20.9%	+12.3%	230
Engagement Bonds	Bond B	+26.0%	+29.1%	118
	Bond C	+50.8%	+21.7%	209
gagem	₩stix	+37.2%	+33.4%	181
gag Bol	Bond D	+19.4%	+8.0%	253
Eng	Bond E	+14.5%	-14.8%	261
	🛚 Арр	+46.0%	+28.9%	199
	Bond F	+24.4%	+0.9%	407
	Total		+8.1% (31 MM)	100
	Loyal	+21.5%	+13.5% (8 MM)	282




By improving our loyalty products, with Stix as a highlight, we drive results and deliver more valuable experiences.

#### Missions 2.0



#### **Benefits Hub**





We accelerate hyper-personalization at scale through GenAI to deliver increasingly relevant experiences.

**Automation of** personalized marketing materials by connecting behaviors. preferences, and journeys.



#### **Expected Impact:**

- ♦ Production of personalized campaigns at scale
- Greater relevance and engagement in communications
- **♦** Synergy between predictive and creative intelligence (NBO + NBA)
- ♦ Increase in conversion and customer value



Application across different communication channels.




National

Regional

# The 2025 communication calendar strategy combined regional execution with national strength, delivering tangible results.

#### 2025 Communication Calendar, Drogasil/Raia brands



**121 MM** people impacted 20+ times

**140+** influencers activated

17 new formats launched

+9 pp in preference for Drogasil

+7 pp in recent Raia purchases

+13.5% loyal customers YoY

**24x** per year, average purchases by loyal customers

+33% Stix customers




# MELISSA CABRAL

VP OPERAÇÕES DE FARMÁCIA


**VP-PHARMACIES** 



# We build our value proposition from the customer's perspective, with customer service as our primary differentiator.









We build our value proposition from the customer's perspective, with customer service as our primary differentiator.

#### **Centennial Culture**

- Customer trust in our people
- o Cordiality, emotional connection, and care
- Pharmacists as community health agents








#### **Continuous evolution of Customer Service tools**

Relationship Terminal (RT)







MIA (My AI)
Virtual assistant for personalized customer service



# Fulfilled & skilled people are the cornerstone of our Employee Value Proposition (EVP), reinforcing differentiation in customer service & efficiency.



#### **Career and Development**

100% of Operations leadership is promoted internally.

**10 Regional Directors**Average of 24 years with RD

**140 Regional Managers**Average of 19 years with RD

**3,500 Managers**Average of 10 years with RD

**New Positions**Manager II and Pharmacist II

#### **Education and Development**

- 。 8,200 Promotions
- 4+ MM hours of training
- ∘ 53,000+ employees trained
- Pharmacy undergrad course

#### **Work Schedule**

Health and efficiency are our commitments.

#### **Operations**


- Pharmacy staff increase
- 。 New 5x2 schedule
- Hazard pay for specific roles

## Simplification of over 70 processes

- PBM flow
- Univers activation
- Farmácia Popular program
- MIA AI-powered assistant
- Price tag printing
- Inventory counting



In parallel, we implemented the new pharmacy system (RT), empowering the team to deliver personalized and efficient customer interactions.





- Relevant data and metrics
- o Compliance with Data Protection laws

## **Recommendations**

- Redesign of the HPC search journey
- In-store ordering (infinite shelf)

## Omnichannel

- Store service connected to app and website
- View of "abandoned cart" in digital channels


## **Consultative Service**

- 55% of consultations during customer contacts
- 45% focused on internal procedures
- 2.3 million interactions in the chat



In parallel, we implemented the new pharmacy system (RT), empowering the team to deliver personalized and efficient customer interactions.


#### Product Search Area



- 'Orientation' tab adapted for counter consultations
- Integration with AI-based validation system

- Complementary suggestions for each shopping basket
  - 。 Data integration

#### Next steps: enhancing recommendations





## With a health strategy based on primary care, we strengthened our connection with customers and achieved an NPS of 93 for in-store services.

## Exploring opportunities in primary care

#### Pharmacy Services


- Vaccinations
- Injectables
- Rapid Tests & CATs (e.g. blood glucose)
- o Orientation for acute cases


#### Care support

- o Treatment adherence
- Treatment support
- 。 Univers enrollment
- Dose Certa (SafePill)
- o Customer programs and journeys


#### Health management

 Univers and Healthbit: reducing disease progression and claims in high-cost groups.






Frequent customer	Avg. Spend (RD = 100)	Frequency (sep/25 YTD)	Loyal
RD Total	100	3.6	25%
Health bond	255	7.5	54%
Vaccinations	446	9.7	73%



Vaccinations beyond flu						
Rev. Participation	2023	2024	2025			
% Flu Vaccine	45%	16%	15%			
% Other Vaccines	55%	84%	85%			







# DIEGO KILIAN

**DIRETOR MULTICANAL** 

**DIRECTOR - OMNICHANNEL** 




E-commerce aims to deliver the best experience, matching the pharmacy NPS...






## Digitalized and engaged customers drive our results.

We raised the bar for Omnichannel solutions					
	RD Customer	Omni Customer	Variation vs. total		
Avg spending casual customer (R\$, index 100)	100	220	+120%		
Frequency casual customer (per year)	2.9x	3.2x	+10%		
Avg spending loyal customers (R\$, index 100)	100	127	+27%		
Frequency loyal customers (per year)	<b>7.2</b> x	<b>8.9</b> x	+23%		






Digitalization has strengthened the relationship and increased customer frequency, reinforced by the engagement of the pharmacy experience.





We continuously improve the shopping experience, developing new features to support the customer in their journey.






We prepared the app to deliver the best navigation at the most promotional date of the year.

#### **Black Friday 2025 Home Page**



Targeted banner (by customer variables)





Cyber Week

01 to 06/Dec

Não da pra ignorar


a última oportunidade de


needs

**ENTREGA EXPRESSA** 




We advanced in digital health, expanding our portfolio of health services & products available to customers.







We improved the app shopping experience, closing the gap with digital leaders and strengthening our differentiation in the pharma channel.






### We improved the last-mile experience and efficiency.

### Live tracking in constant evolution



### Intelligent order allocation


Pharmacy order allocation algorithms balancing operational capacity and delivery speed.



Reduction of ~1 pp in cancellations due to stockouts.

### Scheduled delivery

Scheduled Delivery is now available in all regions with Rapid Delivery.



### In-pharmacy Lockers for Click & Collect


Pilot with lockers, allowing a quick and unassisted collection of digital orders.






# We added to the app a diversified delivery portfolio, contributing to the evolution of our digital NPS.







#### Milestones 3Q25

**94%** of rapid delivery orders made on time

**95%** of deliveries completed with the full basket

**39 min** average Rapid Delivery

**8.1** customer score on *Reclame Aqui* 

**94%** Customer Support satisfaction rating




In the after-sales journey, we evolved in our support communication, migrating transactional messages to WhatsApp and improving the chatbot.

### Transactional messaging through WhatsApp



### Inclusion of live-tracking links in apps and websites



#### Highlights

**-2 pp** in the Customer Support contact rate, despite the +82% increase in the volume of orders (vs 4Q23)

**73**% chatbot retention in the 3Q25 (vs 4Q23)



# Q&A



# COFFEE BREAK



# JULIANA LOPES

**VPCOMERCIAL** 

**VP - COMMERCIAL & PRIVATE LABEL** 



We reaccelerated growth in HPC with a focus on value proposition and an even tighter partnership with suppliers.

#### IMPROVEMENTS TO THE VALUE PROPOSITION WITH IMMEDIATE IMPACT




**Price** 

**Product** 

- Recovery of **digital competitiveness** in key products
- Greater online and offline promotional intensity
- Supplier partnerships for channel management










In the past 2 years, we increased promotional intensity in HPC, offset by product mix improvements, supplier partnerships, among others.





We reaccelerated growth in HPC with a focus on value proposition and an even tighter partnership with suppliers.

#### IMPROVEMENTS TO THE VALUE PROPOSITION WITH IMMEDIATE IMPACT



**Price** 

- Recovery of **digital competitiveness** in key products
- Greater online and offline promotional intensity
- Supplier partnerships for channel management



**Product** 

- Greater in-store inventory availability
- Portfolio differentiation through private label and exclusive product launches



**Customer Service** 

- Recovery of pharmacy staffing levels, for a more **dedicated and advising** service
- Increase in the number of beauty consultants



Service / Convenience


- Increased usage of **rapid delivery** in under 60 minutes
- We are the channel chosen by 4.4 MM beauty customers every month (+9.1% YoY)



**Ambience** 

Evolved digital experience with a focus on the beauty journey







# We elevated our value proposition in HPC with a high-standard experience in our apps...

New exclusive areas for Beauty




Content spotlights in product pages





Virtual try-on POC




- Omnichannel experience
- Specialized advisory service
- Infinite shelf
- SKU variants

Among other improvements...



...and soon in our pharmacies...





We are creating a new beauty & wellness format for the 2H26, establishing an additional moat derived from our omnichannel strengths.





### We established a clear roadmap to elevate our Private Label execution.

#### **Phase 1: Up to 2020**

### Portfolio creation

- Initial objective of category profitability
- Brand creation and positioning
- First products in commodity categories with lower brand relevance

#### Phase 2: 2020-2025

# Innovation and improved supply chain management

- Growing brand recognition by customers
- Portfolio expansion into innovative categories
- In-depth supply chain mgmt. (product supply, quality, ESG)

#### Phase 3: 2025-2030

### Recognition, loyalty & new frontiers

- Top positioning of brands at a national level
- Reason to go to the pharmacy and customer bonds
- Omnichannel strategy, elevating Digital to the same level as the pharmacies
- Entry into sophisticated categories through partnerships & innovations

needs

CARE>TECH

Nat2

needs natos

NUTRI GOOD

bwell



# Needs is the 3<sup>rd</sup> largest consumer health brand in Brazilian pharmacies, elevating RD Saúde as the 16<sup>th</sup> largest supplier.





#### Private label brands in leading positions in RD













+12.9%


Private Label customers
Oct/25 vs. Oct/24



We built our private label brands over the years with growing relevance and high profitability.



R\$ billions, as a % of gross revenue. Front-store = OTC+HPC.



CAGR 2020-25 +**26%** 

Average gross margin
+15 pp
vs. front-store ex-Private Label

Private label market share

33.5%

(Source: IQVIA Jun/25 MAT)

2/3 of customers with front-store profiles also have the private label bond



We are approaching globally recognized pharmacy players, acquiring insights towards improving our value proposition.



International benchmarking with meetings and visits





Solutions for the entry into new segments and for differentiated positioning

Access to innovative brands with global reach

Synergies with the beauty & wellness format



We initiated private label operations in 20+ OTC medicine molecules, with the regulatory window of opportunity for future launches now ended.









20+ approved molecules representing ~16% of RD's OTC



Coverage of

3/4

of OTC medicine customer journeys



2023

Structuring: business, teams & processes

2024

Partnerships, ANVISA approvals & pilot

2025

Contract signing and end of the regulatory window

2026+

Rollout: production and sales at scale



# PAULO SANCHEZ


DIRETOR ENGENHARIA E EXPANSÃO

**DIRECTOR - EXPANSION** 



# We extended the guidance of 330 to 350 gross openings per year up to 2026, maintaining the same recent geographic and demographic diversification.








Expansion errors take into account closures in the same year as their respective opening.



# Nationwide presence, with greater consolidation in the most relevant markets and continued expansion into smaller cities.












Our nationwide physical expansion strengthens our digital channels and vice versa, creating a unique omnichannel experience.






In the recent expansion cycle, 84% of openings were in locations with less than 15% market share.








The accelerated expansion requires a logistics network capable of keeping up with the new challenges.










Brazil's 1<sup>st</sup> fully automated pharmacy distribution center, in Viana/ES, setting the standard for the next wave of efficiency and scalability.





#### **Inventory Optimization**

Greater density and organization



#### **Productivity**

Increase in the pace of picking and shipping



#### **Operational Flexibility**

Allows productivity to scale on demand



#### **Error Reduction**

**Greater reliability** in deliveries



#### **Safety in Handling**

Fewer forklifts, greater protection for people



Our Supply Chain is constantly evolving to drive efficiency and cost savings, while fostering our commitments to the planet.

#### **Cold chain**



Expansion of our cold chain capacity **leveraging GLP-1 operations**.

#### **Electric Trucks**



60 electric trucks (+40), reducing emissions and improving comfort in pharmacies (noise/smog).

#### **CNG Trucks**



Ideal for long routes, reducing **772 tons of CO<sub>2</sub>** per year.




# FERNANDO VARELA

VP TRANSFORMAÇÃO DIGITAL

**VP - DIGITAL TRANSFORMATION** 




# Our investments have made us a digitally ready company with best practices and assets that set us apart in the retail sector.






Our digital transformation began in 2019, with expenses growing +139% over 5 years compared to revenue. We are now capturing the operational results.





# New Digital VP, redesigned and more business-oriented. Artificial Intelligence and Data Analytics permeate the entire organization.





### We've organized our AI agenda into two strategic fronts.

Criteria	Go Deep	Go Wide
Objective	Evolve the customer experience and transform processes and businesses	Solutions rollout to the system
Complexity	High	Low/Medium
Impact Focus	Finance and Customer (margin, sales, costs, NPS)	Operational (workload, FTEs, time)
Responsible Area	Data Science	BI (now BI+AI) (Vibe Coding)
Governance	VPs+Directors Quarterly Workshops	Decentralized (Hackathon, workshops, etc.)
Examples	Zero Risk MIA	Legal Automation Hackathon



Processes marked by governance and the construction of an ecosystem with relevant impacts on results.

#### 100+ use cases driven by data science

#### Governance

#### **Participants**

C-level and Directors Data & Technology teams

#### **Scope of Activities**

- Use cases tracking
- ♦ Project prioritization
- Opportunity hunting
- Quarterly meetings

#### **Examples of cross-sector allocations**

#### Catalogue

Optimize Descriptions Impact (R\$): \$\$

#### **Store Operations**

Comments NPS Impact (R\$): \$\$

#### **Supply**

Inventory Rotation Impact (R\$): \$\$\$\$

#### **Omnichannel**

Analysis Approval Impact (R\$): \$

#### **E-commerce Pricing**

Scenario Simulator Impact (R\$): \$\$

#### **Trade**

Sales Comparison Impact (R\$): \$

#### **Solutions**

Bayesian + LightGBM LLM Haiku 3.0 / MILP

Matrix Profile

**NARMAX** 

**Neural Network** 

NLP

Reinforcement Learning

Titan Multimodal

**XGBoost** 

#### **Ecosystem**






Go Deep: Al projects conducted by the Data Science team in various sectors of the company.

Use Case 1

Supply: Minimizing sales projection error



#### **Problem**

Better sales forecasting to plan purchases, inventories and supply.

#### **Technical Solution**

**Al model** that predicts demand for the next 12 months.


#### Result

Reduction in purchases of \$\$\$ with no impact on stockouts and an increase of \$ in sales.

Reduction of up to 3 working days/month of the S&OP team.



# Go Deep: Al projects conducted by the Data Science team in various sectors of the company.



#### **Problem**

Deliver relevant and personalized experiences to 51 MM customers with agility and efficiency.

#### **Technical Solution**

**GenAl agent** architecture creating contextualized content for a broad range of touchpoints.

#### Result


SLA from 10 days to 10 minutes. Cost reduction and revenue gains of \$\$



Go Deep: Al projects conducted by the Data Science team in various sectors of the company.

#### Use Case 3

Health/Operations: RT navigation



#### Problem

The need for **efficient access** to health services in pharmacies (medication interactions, dosages, etc.)


#### **Technical Solution**

Access via **AI assistant (MIA)** in the RT to standardized information provided by **AI agents.** 

#### Result

Pharmacies equipped with an assistant for medicine interactions, drug information, vaccines, dosage instructions, teleprompter, etc., ready to operate in the Health.

### Use Case 4



#### Problem

Refine the cannibalization estimation and IRR considering the fast pace expansion of new pharmacies

#### **Technical Solution**

Predictive machine learning that considers geographic data, demographics, etc.

#### Result

Greater assertiveness in Expasion capital allocation. Result: \$\$\$



We continue to advance on structural fronts that permeate the entire company, with continuous opportunities to capture efficiencies.



#### **Pharmacy Operations**

#### **Current scenario**

Outsourced consulting firm finalizing the mapping of **productivity opportunities** in pharmacy processes

#### Plan

Scientist allocation and Operations prioritization

Integration



#### **Shared Services Center**

#### **Current scenario**

Outsourced consulting firm mapped 20+ cases of <u>task</u> <u>automation using AI</u>, impacting 50 FTEs

#### **Plan**

Automations with the creation of Al agents





#### Customer Support

#### **Current scenario**

Customer Support already upholds good retention levels but has room to expand the adoption of digital solutions.


#### Plan

New processes using GenAl

Google



We are moving forward with the RD Flow platform, that integrates LLMs for developing digital products with progressive efficiency.





In 2025, we are undertaking initiatives to enable departments to solve their own pain points with technical support and low-complexity tools.

Criteria	Go Deep	Go Wide
Objective	Evolve the customer experience and transform processes and businesses	Solutions rollout to the system
Complexity	High	Low/Medium
Impact Focus	Finance and Customer (margin, sales, costs, NPS)	Operational (workload, FTEs, time)
Responsible Area	Data Science	BI (now BI+AI) (Vibe Coding)
Governance	VPs+Directors Quarterly Workshops	Decentralized (Hackathon, workshops, etc.)
Examples	Zero Risk MIA	Legal Automation Hackathon



# We are advancing with an AI culture and its decentralized adoption, boasting several initiatives already underway with others emerging.

#### New fronts



#### **Hackathons**

Construction of impactful projects



#### **AI Academy**

Biweekly meetings on AI tools



#### **External Benchmarks**

External case sharing & best practices



#### **Executive Training**

Tools and agent building



#### **AI Community Creation**


Engage Network, ambassadors & enthusiasts, success stories, news & tips sharing, etc.)



#### **Exhibition of Real Cases**

Wide dissemination of AI success stories

#### Al Committee



#### Objective

Al governance for **legal** and **responsible use.** 

#### Meetings


- Monthly working groups
- Bi-monthly with leaders from various areas

#### Agenda

- Processes and security status reports
- **Compliance** with regulatory frameworks
- Ethics policies & sanctions enforcement



## We organized our 1st Hackathon mobilizing 20+ areas of the Company.















## Clear and structured roadmap to accelerate impact.

#### Culture & People

#### **♦** Maturity:

- Data-driven decisions
- Accelerate the learning curve in Al

#### **Training and team investment:**

- Training for employees
- Increase operational capacity to meet the volume of use cases
- Partnerships with universities, startups, and innovation ecosystems

#### **Governance & Performance**

#### **♦** Al Control Tower:

- Agent Orchestration
- o Portfolio and budget management

#### Corporate-level dashboard:

。 KPIs to track AI advancements

#### Dedicated team for innovation:

Taskforce team for specific studies,i.e. Shopping Agent

#### **Technology & Infrastructure**

#### **†** Training and team investment:

Multi-cloud and scalable infrastructure

#### Data Foundation & Quality:

In-bound data, deployment pipelines & QA testing

#### Plug & Play infrastructure:

。 Agent / Multi-agent ready

#### **♦** Security:

Bot, malware & privacy agents




# FLAVIO CORREIA

DIRETOR EXECUTIVO DE RELAÇÕES COM INVESTIDORES E ASSUNTOS CORPORATIVOS

**EXECUTIVE DIRECTOR - INVESTOR RELATIONS & CORPORATE AFFAIRS** 




RD Saúde navigated through several political and inflationary scenarios, maintaining consistency and capturing results.







We have consistently expanded our leadership in the long-term, building a nationwide network, at a fast pace and detached from peers.






## We have a solid financial performance.







<sup>\*</sup> Excludes the effects of additional taxation from Law 14,789/23.



### And an active ESG agenda.

#### Governance



**Since 1905,** stewardship of founding families



~75% de free float, with the remainder held by the controlling shareholders



Shareholder agreement until 2031

#### Healthier People and Businesses



**65%** of female leadership & inclusion policies for PwD, LGBTQIA+, 50+



100% of pharmacy leaders developed within RD Saúde



**100h** of training & **2k** professionals impacted by undergrad/grad programs

#### Improving recognition of our ESG efforts ISEB3 52 67 76 **83** 100 D MSCI В BB **BBB** CCC AAA 2023/2024 2020 2021 2022

#### Healthier Planet



**100%** of operations supplied by renewable sources



**100%** stores w/ disposal bins & recyclable private label packaging



**Health** via digital plat.: vaccines, serv. & CATs



Measuring & reduction scopes 1-2 **emissions** (-39%) & scope 3 awareness agenda



Route planning, effiicient truck loading & **fleet** electrification



ISO 14.001 & ISO 45.001 **certification** & DC/Campus LEED

#### **IDIVERSA** B3

Launched in Aug/23 with companies that stand out in terms of **diversity**.




ISO / IEC 27001 2022 (BSI)



Information Security and privacy/LGPD certification on Digital Channels (Apps and Websites) and Univers PBM.

#### Most valuable Brazilian brands


Source: Interbrand MBMV 24/25




# We have built the only two HEALTH brands among the most valuable in the country.




We continue to expand and consolidate in an consistently growing market while maintaining superior unit economics.











<sup>\*</sup> Mature stores. 4-wall EBITDA does not consider DCs or regional expenses.



Well positioned to capture new optionalities with GLP-1 drugs in Brazil, remaining the most relevant channel.





#### **Supply** End of Patent

Stabilized inventories, covering all current and new dosages


In 2026, expanding the market with new launches, volumes, prices and access

## Developments

New molecules, pharmaceutical presentations and use combinations



## We defined priorities to guide the company's evolution





# Results already captured, combined with additional events, create a positive environment for RD Saúde.

# Recovery of Performance & Efficiency

- Price and competitiveness
- HPC performance
- Enphasis on Logistics and supply
- Inventory levels and losses
- Corporate review (G&A)
- Optimization of investments in strategic initiatives
- Culture and engagement (EVP)

# **Strengthening of the Value Proposition and Moats**

- Evolve in our value proposition for customers
- Evolve even further in the in-store digital experiences
- Evolve in the culture of efficiency
- Evolve in the use of AI
- Advance our private labels
- Accelerate value of our adjacencies (Impulso and compounded drugs)
- Increase proximity / Expansion


# Gains in Scale and Market Share

## Established moats add to a favorable context

- GLP-1 Opportunities
- Tech & Al investment power
- Natural digitalization of the customer
- Tax reform
- A solid balance sheet in a high SELIC interest rate scenario



# How does the Flywheel strengthen our competitive advantages and accelerate our growth?



- Centennial culture of care
  Since 1905 and with NPS 91
- Nationally recognized brands
  Raia and Drogasil among the 20 most valuable brands
- Proximity to the customer 82 million customers just 1.5 km away
- Regional managers with 19y at RD With careers built within the Company
- Modern store footprint
  3.5k pharmacies, of which 3k opened since Jan/12
- Digital journey via proprietary channels 27% of retail sales, of which 81% via apps





# Q&A





# CLOSING